Notícias e Atividades da Vedanta Biosciences

Veja o organograma con seus 33 executivos principais

Biografias mais buscadas da Vedanta Biosciences

• Bernat Olle, Chief Executive Officer and Director
• Andrew Davis, Director
• Sue Dillon, Board Member

Recentes movimentos de executivos em Vedanta Biosciences

• Jeffrey Silber, Chief Medical Officer, deixará a Companhia em 20 de jul. de 2026  (Notícia publicada em 15 de julho de 2026).

Criar um alerta
para seguir os movimentos de executivos da Vedanta Biosciences.

Vedanta Biosciences possui 2.429 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Tempus has announced the acquisition of Personalis  (publicado em 20 de julho de 2026).
• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Patrick Enright - Director da CuraSen Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Vedanta Biosciences

• Vedanta Biosciences Completes $68 Million Series D Financing :: Vedanta Biosciences, Inc.
• Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC) :: Vedanta Biosciences, Inc.
• Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event :: Vedanta Biosciences, Inc.
• Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit :: Vedanta Biosciences, Inc.
• Vedanta Biosciences to Present at Upcoming Investor Conferences :: Vedanta Biosciences, Inc.
• Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer :: Vedanta Biosciences, Inc.
• Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc. :: Vedanta Biosciences, Inc.
• Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors :: Vedanta Biosciences, Inc.
• Vedanta Biosciences Announces Additional Pharmacokinetics Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease to be Presented at United European Gastroenterology Week 2020 :: Vedanta Biosciences, Inc.
• Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients :: Vedanta Biosciences, Inc.
• View more press releases Close

Redes sociais sobre Vedanta Biosciences

• Vedanta Biosciences na Wikipedia, Google News e Yahoo Finance
• Vedanta Biosciences na LinkedIn, X (Twitter) e YouTube